If pregnancy occurs during treatment, the medication should be stopped immediately and healthcare providers notified
The phase 2 studies employed a range of 1 mg to 12 mg weekly doses, with most participants reaching target doses within 24 to 36 weeks
Search for retatrutide and filter by status to find trials that are currently recruiting
Now it takes everything you have just to get through the week and your doctor says your labs are normal
Novo Nordisk has sought FDA approval for a higher-dose version of oral semaglutide to treat obesity, which may arrive later this year
Phase 2 trial (NEJM, 2023) The landmark Phase 2 trial, published in the New England Journal of Medicine, randomized 338 adults with obesity to receive weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks